Merck Serono receive EU approval for Erbitux in Metastatic Colorectal Cancer

Posted on July 23, 2008 by crimsoncanary

Merck Serono have received EU approval for Erbitux in EGFR expressing, KRAS wild-type metastatic colorectal cancer

Filed under: Kinase receptor | Tagged: , , , , , , , , | Comments Off

Everolimus can improve progression-free survival in advanced renal cell carcinoma

Posted on July 23, 2008 by crimsoncanary

Data published in the Lancet shows that treatment with mTOR inhibitor everolimus can significantly improve progression-free survival in patients with advanced renal cell carcinoma who have not responded to other targeted therapies.

Filed under: kinase | Tagged: , , , , , | Comments Off

AstraZeneca/Array publish series of Trk kinase inhibitors

Posted on July 23, 2008 by crimsoncanary

AstraZenexa and Array Biopharma have published a series of 4-aminopyrazolylpyrimidine Trk kinase inhibitors

Filed under: kinase | Tagged: , , , , , | Comments Off

Tekmira to advance PLK-1 SNALP to Phase I in 2009

Posted on July 23, 2008 by crimsoncanary

Tekmira Pharmaceuticals have announced plans to advance its RNA interference (RNAi)PLK1 ‘SNALP’ product in to clinical development in 2009

Filed under: kinase | Tagged: , , , , | Comments Off

Silence Therapeutics awarded EP patent for siRNA targeting protein kinase N beta

Posted on July 23, 2008 by crimsoncanary

Silence Therapeutics have been awarded an european patent for its lead compound, Atu027, a siRNA that targts protein kinase N beta (EP 03790894.4)

Filed under: Uncategorized | Tagged: , , , | Comments Off